🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Locally Advanced Esophageal Cancer

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma NCT03556228Phase 1, Phase 215 sites📍 Santa Rosa📍 Hartford📍 Washington D.C. VM Oncology, LLC · Tests: VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg) Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) NCT06780111Phase 1, Phase 252 sites📍 Pittsburgh📍 Natal📍 Porto Alegre Merck Sharp & Dohme LLC · Tests: Pembrolizumab, I-DXd, Leucovorin, Levoleucovorin, 5-Fluorouracil (5-FU) Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma NCT05937438Phase 1, Phase 21 site📍 Hefei Anhui Provincial Hospital · Tests: Immune Checkpoint Inhibitors A Phase II Study of Toripalimab Combined With Sequential Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma NCT06843889Phase 21 site📍 Guangzhou Nanfang Hospital, Southern Medical University · Tests: Toripalimab (240mg day1, Q3W*3cycle) Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma NCT06988956Phase 21 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: Nimotuzumab, Tegafur, radiotherapy Efficacy and Safety of Penpulimab Combined With Anlotinib and Chemotherapy NCT06586242Phase 21 site📍 Xi'an Xijing Hospital · Tests: Penpulimab;Anlotinib;albumin paclitaxel;oxaliplatin;lobaplatin Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma NCT07559045Phase 21 site📍 Zunyi Second Affiliated Hospital of Zunyi Medical University · Tests: Paclitaxel plus Cisplatin or Carboplatin (Induction Chemotherapy), Weekly Paclitaxel plus Cisplatin or Carboplatin (Con… Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma NCT06446726Phase 21 site📍 Chengdu Sichuan University · Tests: Tislelizumab, Low-dose radiotherapy, Nab-paclitaxel, Cisplatin Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell Carcinoma NCT06912074Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Induction chemoimmunotherapy, Hypofractionated Radiation Therapy, Conventional Fractionated Radiation Therapy, Concurre… A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors NCT06008054Phase 21 site📍 Beijing Sichuan Baili Pharmaceutical Co., Ltd. · Tests: SI-B003, BL-B01D1, PD-1 Monoclonal Antibody Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC NCT07038629Phase 21 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: S1, Iparomlimab, Radiation Adaptive RadioTherapy for OroPharynx Cancer NCT04901234Phase 22 sites📍 Melbourne📍 Montreal Centre hospitalier de l'Université de Montréal (CHUM) · Tests: Standard radiotherapy +/- chemotherapy, Experimental radiotherapy +/- chemotherapy Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma（CRIS-2 Trial） NCT06509568Phase 21 site📍 Hangzhou Zhejiang Cancer Hospital · Tests: Neoadjuvant chemoradiotherapy followed by immunotherapy, Neoadjuvant chemoimmunotherapy A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor NCT05262491Phase 16 sites📍 Beijing📍 Nanchang📍 Jinan Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-B01D1 Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC NCT06510660Phase 21 site📍 Fuzhou Fujian Medical University Union Hospital · Tests: adebrelimab EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors NCT07410676Phase 1, Phase 21 site📍 Beijing Essen Biotech · Tests: EBNK-001 + IL-15 + Pembrolizumab Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors NCT06975410Phase 1, Phase 24 sites📍 Seoul📍 Seoul📍 Seoul Yuhan Corporation · Tests: YH32364 A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Esophageal Squamous Carcinoma NCT06869213Phase 21 site📍 Beijing Peking University Cancer Hospital & Institute · Tests: Adebrelimab (SHR-1316) + Nab-paclitaxel + Cisplatin A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F) NCT07405151Phase 1, Phase 232 sites📍 Pittsburgh📍 Natal📍 Porto Alegre Merck Sharp & Dohme LLC · Tests: I-DXd, Rescue Medication Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer NCT04415853Phase 31 site📍 Beijing Sunshine Lake Pharma Co., Ltd. · Tests: Lerotinib, Irinotecan/Tegafur Sacituzumab Govitecan Combined With Tislelizumab for Locally Advanced/Metastatic Esophageal Cancer NCT07811752Phase 22 sites📍 Shanghai📍 Shanghai Shanghai Chest Hospital · Tests: Sacituzumab Tirumotecan (SKB264) plus Tislelizumab Home Monitoring During Chemoradiation NCT06597240n/a1 site📍 Groningen University Medical Center Groningen · Tests: AMCOR Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC NCT04973306Phase 2, Phase 31 site📍 Shanghai Shanghai Zhongshan Hospital · Tests: Neoadjuvant Chemoradiotherapy, Tislelizumab, Ivor-Lewis or Mckeown Esophagectomy(Mckeown Esophagectomy recommended) Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer NCT05267626Phase 1, Phase 217 sites📍 Miami📍 Grand Rapids📍 Minneapolis Aulos Bioscience, Inc. · Tests: AU-007, Aldesleukin, Avelumab, Nivolumab Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma NCT05495152Phase 32 sites📍 Zhengzhou📍 Zhengzhou Henan Cancer Hospital · Tests: Sintilimab A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS) NCT06709417Phase 21 site📍 Shanghai Shanghai Chest Hospital · Tests: Sintilimab, Chemotherapy, radiotherapy DBC-664 in Adult Patients With Solid Tumors NCT07705035Phase 17 sites📍 Denver📍 Grand Rapids📍 St Louis Duboce Biopharmaceuticals, Inc. · Tests: DBC-664 A Study of SH009 Injection in Patients With Advanced Solid Tumors. NCT07390838Phase 11 site📍 Shanghai Nanjing Sanhome Pharmaceutical, Co., Ltd. · Tests: SH009 Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program NCT06265285Phase 21 site📍 Jacksonville Mayo Clinic · Tests: Home Health Encounter, Nivolumab, Patient Monitoring, Questionnaire Administration Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma NCT06410651Phase 21 site📍 Beijing Cancer Institute and Hospital, Chinese Academy of Medical S… · Tests: Nimotuzumab with chemoradiotherapy
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy